JTO: PET/CT can be used to fast track lung cancer diagnosis

PET/CT can be used to diagnose lung cancer in a “fast-track” setting, according to a study published in the October issue of the Journal of Thoracic Oncology.

Tjeerd S. Aukema, MD, from the Netherlands Cancer Institute in Amsterdam, and colleagues performed a prospective study on 114 patients with pulmonary symptoms or abnormal chest x-ray who were referred for fast-track assessment at the Netherlands Cancer Institute between March 2005 and September 2007.

According to the authors, evaluation of each patient was done in a multi-disciplinary setting, which included F18-FDG PET, diagnostic CT and bronchoscopy (including biopsy), with histopathological evaluation as the reference standard. The fast-track model tested patients over the course of one day.

In 92 percent of the patients a final diagnosis was achieved. Malignancy was diagnosed in 84 percent of the patients, non-small cell lung cancer in 67 percent, small cell lung cancer in 7 percent and metastases or other malignancies in 10 percent. Sensitivity, specificity, accuracy, positive predictive value and negative predictive value of PET/CT for the presence of malignancy were 97, 56, 90, 92 and 77 percent, respectively.

The authors noted that almost half of the patients with a malignancy were scheduled for curative treatment--29 patients for surgery and 14 patients for chemoradiotherapy.

"Our approach resulted in a fast and accurate diagnosis and allowed for treatment to be initiated without delays." said Aukema. "These results suggest that availability of fast-track assessment facilities can contribute to appropriate and timely evaluation of lung malignancies."

On the basis of their findings, the researchers concluded that in a outpatient fast-track setting, PET/CT provides "valuable information for diagnosing lung cancer, with a high positive predictive value, and is useful for clinical decision-making."
Michael Bassett,

Contributor

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.